Retatrutide vs CagriSema: The Two Most Powerful Pipeline Drugs Compared

If you’re tracking the highest-efficacy weight-loss drugs still in development, retatrutide and CagriSema are the two names that matter most, and retatrutide currently holds the edge on weight loss. Both have produced results in the low-to-high 20% range, far beyond first-generation drugs, but they work through entirely different mechanisms. Neither is FDA approved yet. Retatrutide is a triple hormone agonist; CagriSema is an amylin-plus-GLP-1 combination. Here’s how the two frontrunners stack up.

Two Different Roads to Big Weight Loss

These drugs reach similar heights through different strategies. Retatrutide activates three receptors at once (GIP, GLP-1, and glucagon), with the glucagon component adding increased calorie burning. CagriSema takes a different route, pairing semaglutide (a GLP-1 drug) with cagrilintide (an amylin drug), combining two appetite-regulating hormones. So one drug goes wide across three pathways, while the other doubles up on appetite control specifically.

Head to Head

Here’s how they compare on the key points.

Weight Loss: Retatrutide Leads

On raw weight loss, retatrutide appears to be ahead. Its phase 2 data, published in the New England Journal of Medicine in 2023, showed about 24% weight loss at the highest dose over 48 weeks, and later phase 3 results pushed toward 28%. CagriSema, in its REDEFINE 1 trial, produced about 22.7% over 68 weeks. The two are in the same tier, but retatrutide’s triple mechanism seems to give it a modest advantage, and its weight loss was still climbing in longer studies. That said, comparing across separate trials is imprecise, so the gap should be read as approximate.

Development and Availability

CagriSema is slightly ahead on the regulatory path: Novo Nordisk filed for FDA approval in late 2025, with a decision expected in 2026. Retatrutide is a bit further back, with a regulatory submission anticipated as its phase 3 program completes. Neither is available yet outside clinical trials. Consider a hypothetical patient hoping to access one of these soon: CagriSema may reach the market a little earlier, but both are still in the pipeline, and timelines can shift.

Side Effects

Both cause the familiar gastrointestinal side effects (nausea, vomiting, constipation), mostly mild to moderate. CagriSema, being a two-drug combination, tends toward higher rates of these. Retatrutide adds its own distinctive effect: a skin-tingling sensation (dysesthesia) at higher doses that CagriSema doesn’t typically produce. So the tolerability trade-offs differ, and neither is clearly gentler overall.

What This Means for You Right Now

Neither retatrutide nor CagriSema is available, and TrimRx does not offer them. TrimRx provides currently available options, including compounded semaglutide and compounded tirzepatide plus brand injectables like Ozempic, Wegovy, Mounjaro, and Zepbound. If you want strong weight loss you can start now, tirzepatide-based treatment is the most powerful approved option currently available while these two frontrunners complete development.

Frequently Asked Questions

Which is more effective, retatrutide or CagriSema?

Retatrutide has shown slightly higher weight loss in trials (up to about 28% versus about 22.7% for CagriSema), thanks to its triple mechanism. Both are in the top tier, so the difference is real but modest, and cross-trial comparisons aren’t exact.

Which will be available first?

CagriSema is a bit further along on the regulatory path (Novo Nordisk filed for FDA approval in late 2025). Retatrutide’s submission is anticipated as its phase 3 program finishes. Neither is available yet, and timelines can change.

Can I get either drug now?

No. Both are investigational and available only through clinical trials. TrimRx offers approved alternatives including compounded and brand GLP-1 medications.

To focus on what you can actually start with today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. Retatrutide and CagriSema are investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.